These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 25285035)

  • 1. Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?
    Scheuing L; Chiu CT; Liao HM; Linares GR; Chuang DM
    Int J Biol Sci; 2014; 10(9):1024-38. PubMed ID: 25285035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
    Linares GR; Chiu CT; Scheuing L; Leng Y; Liao HM; Maric D; Chuang DM
    Exp Neurol; 2016 Jul; 281():81-92. PubMed ID: 27085395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.
    Chiu CT; Liu G; Leeds P; Chuang DM
    Neuropsychopharmacology; 2011 Nov; 36(12):2406-21. PubMed ID: 21796107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamotrigine in motor and mood symptoms of Huntington's disease.
    Shen YC
    World J Biol Psychiatry; 2008; 9(2):147-9. PubMed ID: 17853293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington's disease.
    Ransome MI; Renoir T; Hannan AJ
    Neural Plast; 2012; 2012():874387. PubMed ID: 22830053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
    Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
    Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.
    Chiu CT; Wang Z; Hunsberger JG; Chuang DM
    Pharmacol Rev; 2013 Jan; 65(1):105-42. PubMed ID: 23300133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms.
    Giralt A; Saavedra A; Alberch J; Pérez-Navarro E
    J Huntingtons Dis; 2012; 1(2):155-73. PubMed ID: 25063329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers.
    Leng Y; Wang Z; Tsai LK; Leeds P; Fessler EB; Wang J; Chuang DM
    Mol Psychiatry; 2015 Feb; 20(2):215-23. PubMed ID: 24468826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease.
    Tobore TO
    J Neurosci Res; 2019 Nov; 97(11):1455-1468. PubMed ID: 31304621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of psychotropic drugs in Huntington's disease.
    Lauterbach EC
    Int J Mol Sci; 2013 Nov; 14(11):22558-603. PubMed ID: 24248060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significantly differential diffusion of neuropathological aggregates in the brain of transgenic mice carrying N-terminal mutant huntingtin fused with green fluorescent protein.
    Cheng PH; Li CL; Her LS; Chang YF; Chan AW; Chen CM; Yang SH
    Brain Struct Funct; 2013 Jan; 218(1):283-94. PubMed ID: 22422149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
    Podvin S; Reardon HT; Yin K; Mosier C; Hook V
    J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntington's Disease and Mitochondria.
    Jodeiri Farshbaf M; Ghaedi K
    Neurotox Res; 2017 Oct; 32(3):518-529. PubMed ID: 28639241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressants for neuroprotection in Huntington's disease: A review.
    Jamwal S; Kumar P
    Eur J Pharmacol; 2015 Dec; 769():33-42. PubMed ID: 26511378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Advances for Huntington's Disease.
    Kumar A; Kumar V; Singh K; Kumar S; Kim YS; Lee YM; Kim JJ
    Brain Sci; 2020 Jan; 10(1):. PubMed ID: 31940909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for a common mechanism of mood stabilizers.
    Harwood AJ; Agam G
    Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.